Category - Markets

Stifel launched coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and 12-month target price of $23. The stock closed at $11.20 on Friday. “Our bullish thesis centers on two key pipeline assets: AVP...

JMP Securities resumed coverage of AtriCure (NASDAQ:ATRC) with a “market outperform” rating and $25 price target. The stock closed at $14.39 on Wednesday. “AtriCure is well positioned, in our view, to further develop...

Rodman & Renshaw initiated coverage of Catalyst Biosciences (NASDAQ:CLIO) with a “buy” rating and a 12-month price target of $3.50. The stock closed at $1.25 on Wednesday. Using its proprietary protease platform...

Rodman & Renshaw has initiated coverage of OpGen (NASDAQ:OPGN) with a “buy” rating and 12-month price target of $2.50. The stock closed at $1.56 on Tuesday. “In our view, the company’s QuickFISH assays, the latest...

H.C. Wainwright has launched coverage of Vascular Biogenics (NASDAQ:VBLT) with a “buy” rating and 12-month price target of $11. The stock closed at $4.10 on Tuesday. Vascular Biologics, also known as VBL Therapeutics or...

Rodman & Renshaw has initiated coverage of NeuroMetrix (NASDAQ:NURO) with a “buy” rating and 12-month price target of $4.50. The stock closed at $1.74 on Tuesday. NeuroMetrix is a commercial-stage medical device...

Roth Capital Partners has initiated coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $2.75 price target. The stock closed at 60 cents on Friday. “Heat Biologics possesses a portfolio of unique...

William Blair has raised it price target for ARIAD Pharmaceuticals (NASDAQ:ARIA) to $12 from $10 after an analyst day on Friday where the company discussed the outcome of its strategic review. The stock was quoted at $7...

Roth Capital Partners has initiated coverage of PhaseRx (NASDAQ:PZRX) with a “buy” rating and 12-month price target of $8. The stock closed at $5 on Thursday. “In our opinion, PhaseRx’s technology platform, combined...

BTIG Research has initiated coverage of Entellus Medical (NASDAQ:ENTL) with a ‘buy” rating and $22 price target. The stock closed at $18.58 on Monday. “Entellus Medical benefits patients, physicians, and payers by...